Format
Sort by
Items per page

Send to

Choose Destination

Best matches for vansteenkiste-j*:

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC et al. N Engl J Med. (2018)

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Antonia SJ et al. N Engl J Med. (2017)

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. Carbone DP et al. N Engl J Med. (2017)

Search results

Items: 1 to 20 of 307

1.

Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.

Frick AE, Nackaerts K, Moons J, Lievens Y, Verbeken E, Lambrecht M, Coolen J, Dooms C, Vansteenkiste J, De Leyn P, Nafteux P.

Eur J Cardiothorac Surg. 2018 Dec 6. doi: 10.1093/ejcts/ezy385. [Epub ahead of print]

PMID:
30535191
2.

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer.

Vansteenkiste JF.

ESMO Open. 2018 Sep 10;3(6):e000429. doi: 10.1136/esmoopen-2018-000429. eCollection 2018. No abstract available.

3.

Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.

Ghysen K, Vansteenkiste J.

Curr Opin Oncol. 2019 Jan;31(1):13-17. doi: 10.1097/CCO.0000000000000497.

PMID:
30325753
4.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
5.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K.

Lancet Oncol. 2018 Nov;19(11):1468-1479. doi: 10.1016/S1470-2045(18)30673-9. Epub 2018 Sep 24. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30262187
6.

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K.

Br J Clin Pharmacol. 2018 Dec;84(12):2877-2888. doi: 10.1111/bcp.13753. Epub 2018 Oct 10.

PMID:
30171779
7.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW.

J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.

PMID:
30156984
8.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
9.

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue.

Reynders K, Wauters E, Moisse M, Decaluwé H, De Leyn P, Peeters S, Lambrecht M, Nackaerts K, Dooms C, Janssens W, Vansteenkiste J, Lambrechts D, De Ruysscher D.

Radiat Oncol. 2018 Jul 17;13(1):131. doi: 10.1186/s13014-018-1075-1.

10.

Phenotype molding of stromal cells in the lung tumor microenvironment.

Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den Eynde K, Weynand B, Verbeken E, De Leyn P, Liston A, Vansteenkiste J, Carmeliet P, Aerts S, Thienpont B.

Nat Med. 2018 Aug;24(8):1277-1289. doi: 10.1038/s41591-018-0096-5. Epub 2018 Jul 9.

PMID:
29988129
11.

A Randomized Clinical Trial of Flex 19G Needles versus 22G Needles for Endobronchial Ultrasonography in Suspected Lung Cancer.

Dooms C, Vander Borght S, Yserbyt J, Testelmans D, Wauters E, Nackaerts K, Vansteenkiste J, Verbeken E, Weynand B.

Respiration. 2018;96(3):275-282. doi: 10.1159/000489473. Epub 2018 Jun 29.

PMID:
29961053
12.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196.

13.

Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?

Deslypere G, Gullentops D, Wauters E, Vansteenkiste J.

Ther Adv Med Oncol. 2018 May 4;10:1758835918772810. doi: 10.1177/1758835918772810. eCollection 2018. Review.

14.

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.

Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub 2018 Mar 21. Review.

15.

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.

Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Dols MAC, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam S.

Ann Oncol. 2017 Nov 1;28(suppl_10). doi: 10.1093/annonc/mdx782. No abstract available.

PMID:
29718073
16.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
17.

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.

Vansteenkiste J, Wauters E.

Ann Oncol. 2018 Jan 1;29(suppl_1):i1-i2. doi: 10.1093/annonc/mdx724. No abstract available.

PMID:
29462258
18.

Is central lung tumour location really predictive for occult mediastinal nodal disease in (suspected) non-small-cell lung cancer staged cN0 on 18F-fluorodeoxyglucose positron emission tomography-computed tomography?

Decaluwé H, Moons J, Fieuws S, De Wever W, Deroose C, Stanzi A, Depypere L, Nackaerts K, Coolen J, Lambrecht M, Verbeken E, De Ruysscher D, Vansteenkiste J, Van Raemdonck D, De Leyn P, Dooms C; Leuven Lung Cancer Group.

Eur J Cardiothorac Surg. 2018 Jul 1;54(1):134-140. doi: 10.1093/ejcts/ezy018.

PMID:
29447330
19.

Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC.

Vanden Bempt I, Wauters E, Vansteenkiste J.

Ann Oncol. 2018 Apr 1;29(4):789-791. doi: 10.1093/annonc/mdy053. No abstract available.

PMID:
29432543
20.

Immunotherapy in lung cancer.

Vansteenkiste JF.

ESMO Open. 2018 Jan 9;3(1):e000311. doi: 10.1136/esmoopen-2017-000311. eCollection 2018. No abstract available.

Supplemental Content

Loading ...
Support Center